STOCK TITAN

Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

Monopar Therapeutics (Nasdaq: MNPR) has enrolled the first patient in its first-in-human Phase 1 trial for MNPR-101-Zr, a novel radiopharmaceutical imaging agent. This agent combines Monopar's antibody, MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR) with the radioisotope zirconium-89. The trial, led by Prof. Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry in up to 12 patients with advanced cancers. uPAR is a target in aggressive cancers such as pancreatic, triple-negative breast, and colorectal cancers. Preclinical results have been promising.

Positive
  • First patient enrolled in Phase 1 trial for MNPR-101-Zr.
  • Trial aims to assess safety and dosimetry in up to 12 patients.
  • uPAR target found in aggressive cancers like pancreatic and colorectal cancers.
  • Led by internationally recognized nuclear medicine physician Prof. Rodney Hicks.
  • Encouraging preclinical results in several challenging cancers.
Negative
  • None.

The initiation of Monopar's first-in-human Phase 1 trial for MNPR-101-Zr is noteworthy, especially in the context of targeting aggressive cancers such as pancreatic, triple-negative breast and colorectal cancers. The urokinase plasminogen activator receptor (uPAR) is a significant cancer target due to its expression in highly invasive tumors. By utilizing a radiopharmaceutical approach, Monopar aims to leverage the selectivity of MNPR-101, conjugated with Zirconium-89, for both imaging and potential therapeutic purposes.

From an oncology perspective, the safety and dosimetry data generated in this trial will be critical. These factors will determine if the agent can effectively deliver therapeutic doses to targeted cancer cells without causing undue harm to healthy tissues. Additionally, successful dosimetry results could pave the way for subsequent phases focusing on efficacy, moving one step closer to potentially transforming the treatment landscape for these deadly cancers.

Monopar's enrollment of the first patient in the Phase 1 trial for MNPR-101-Zr represents a significant advancement in radiopharmaceutical development. This trial's primary objective is to assess safety and dosimetry—key benchmarks that will inform future clinical trials. The involvement of an expert like Professor Rodney Hicks adds credibility and expertise to the study, enhancing its potential for success.

Importantly, this trial is pioneering in the evaluation of a radiolabeled monoclonal antibody targeting uPAR. The results could offer insights into the biodistribution characteristics of MNPR-101-Zr, providing a foundation for optimizing dosing strategies. For investors, progress in such innovative treatments aligns with future growth and value generation, particularly if the data supports further clinical development.

From a financial standpoint, Monopar's announcement marks a positive development for the company's clinical pipeline. Initiating a first-in-human Phase 1 trial is a critical milestone that can impact investor sentiment and stock performance. The trial aims to gather essential safety and dosimetry data, which could significantly influence the company's valuation and attractiveness to potential investors or partners if successful.

However, it’s important to temper expectations with caution; early-phase trials are inherently risky and uncertain. Investors should consider the broader context of the biopharmaceutical market, where many promising agents do not make it past early-stage trials. Nonetheless, Monopar’s focus on a well-credentialed target in aggressive cancers could potentially offer a high reward if the trial results are positive.

WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. This novel radiopharmaceutical imaging agent combines MNPR-101, Monopar’s antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the radioisotope zirconium-89.

Monopar’s Phase 1 clinical trial, led by internationally recognized nuclear medicine physician Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers. This is the first human study to evaluate a radiolabeled monoclonal antibody targeting uPAR.

“uPAR is a well-credentialed cancer target found in some of the most aggressive, deadly cancers, including pancreatic, triple negative breast, and colorectal cancers. We are very much looking forward to seeing the biodistribution and dosimetry data from this study,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.

“We are pleased to enroll our inaugural patient. Encouraging preclinical results in several challenging cancers underscore the potential of uPAR as a promising target to battle some of the most lethal cancers,” added Andrew Cittadine, Monopar’s Chief Operating Officer.

Further information about this clinical trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers, as well as early development programs against solid cancers. For more information, visit: www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: The Company’s Phase 1 trial aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers; Monopar is very much looking forward to seeing the biodistribution and dosimetry data from this Phase-1 trial; and that encouraging preclinical results in several challenging cancers underscore the potential of uPAR as a promising target to battle some of the most lethal cancers. The forward-looking statements involve risks and uncertainties including, but not limited to: the enrolled patient may not receive the scheduled dose of MNPR-101-Zr; the Phase 1 imaging and dosimetry clinical trial in advanced cancer patients with MNPR-101-Zr may not yield satisfactory results, if at all; that future preclinical or clinical data will not be as promising as the data to date; that MNPR-101-Zr may cause unexpected serious adverse effects in humans; that Monopar may expend available funds sooner than anticipated or require additional funding due to change in circumstances or unanticipated events; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:  

Monopar Therapeutics Inc.
Investor Relations
  
Karthik Radhakrishnan  
Chief Financial Officer  
karthik@monopartx.com

Follow Monopar on social media for updates:
Twitter: @MonoparTx  LinkedIn: Monopar Therapeutics


FAQ

What is MNPR-101-Zr?

MNPR-101-Zr is a novel radiopharmaceutical imaging agent combining Monopar's antibody MNPR-101 and the radioisotope zirconium-89, targeting the urokinase plasminogen activator receptor (uPAR).

What is the purpose of Monopar's Phase 1 trial for MNPR-101-Zr?

The Phase 1 trial aims to assess the safety and dosimetry of MNPR-101-Zr in patients with advanced cancers.

When did Monopar enroll the first patient for the MNPR-101-Zr trial?

Monopar enrolled the first patient for the MNPR-101-Zr trial on July 9, 2024.

Who is leading the Phase 1 trial for MNPR-101-Zr?

The trial is led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre.

What cancers are targeted by MNPR-101-Zr?

MNPR-101-Zr targets cancers with the urokinase plasminogen activator receptor (uPAR), including pancreatic, triple-negative breast, and colorectal cancers.

Monopar Therapeutics Inc.

NASDAQ:MNPR

MNPR Rankings

MNPR Latest News

MNPR Stock Data

11.80M
17.57M
53.48%
2.26%
0.5%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WILMETTE